Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.

Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama N, Otsuki Y, Nakayama S, Miyazaki K.

Anticancer Res. 2012 Aug;32(8):3091-5.

PMID:
22843878
2.

Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.

Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IeM, Miyazaki K.

Cancer. 2012 Jun 1;118(11):2846-57. doi: 10.1002/cncr.26598. Epub 2011 Dec 2.

3.

[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].

Li J, Zhong M, Song LL, Su GD.

Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jun;26(6):824-5. Chinese.

4.

[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].

Zhong M, Li J, Ding YQ, Song LL.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Dec;23(6):665-7. Chinese.

PMID:
17160949
5.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.

Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT.

Mod Pathol. 2014 Jul;27(7):983-90. doi: 10.1038/modpathol.2013.216. Epub 2013 Dec 13.

6.

Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.

Sun G, Zhou J, Yin A, Ding Y, Zhong M.

Int J Oncol. 2008 May;32(5):1065-71.

PMID:
18425333
8.

ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.

Li J, Song L, Qiu Y, Yin A, Zhong M.

Int J Clin Exp Pathol. 2014 May 15;7(6):3038-47. eCollection 2014.

9.

Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.

Huang HN, Huang WC, Lin CH, Chiang YC, Huang HY, Kuo KT.

Hum Pathol. 2014 Nov;45(11):2318-25. doi: 10.1016/j.humpath.2014.07.020. Epub 2014 Aug 16.

PMID:
25281027
10.

[Expression of ZNF217 in human ovarian cystadenocarcinoma and its clinical significance].

Sun GQ, Zhong M, Ding YQ, Su GD, Song TR, Yin AL.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Apr;29(4):685-8. Chinese.

11.

Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer.

Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ.

Clin Cancer Res. 2000 May;6(5):1833-9.

12.

Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.

Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ.

Genes Chromosomes Cancer. 2008 Oct;47(10):873-83. doi: 10.1002/gcc.20592.

PMID:
18615678
13.

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O.

Mod Pathol. 2011 Aug;24(8):1146-55. doi: 10.1038/modpathol.2011.70. Epub 2011 Apr 8.

14.

[Study on amplification of ZNF217 in primary gastric carcinoma].

Zhu YQ, Zhu ZG, Liu BY, Chen XH, Zhang Y, Yin HR.

Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Jan;8(1):60-2. Chinese.

PMID:
16149004
15.

Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.

Watanabe T, Imoto I, Katahira T, Hirasawa A, Ishiwata I, Emi M, Takayama M, Sato A, Inazawa J.

Jpn J Cancer Res. 2002 Oct;93(10):1114-22.

PMID:
12417041
16.

CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.

Plevova P, Cerna D, Balcar A, Foretova L, Zapletalova J, Silhanova E, Curik R, Dvorackova J.

Neoplasma. 2010;57(4):325-32.

PMID:
20429623
17.

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.

Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB.

Int J Gynecol Pathol. 2005 Apr;24(2):147-52.

PMID:
15782071
18.

[ZNF217 expression correlates with the biological behavior of human ovarian cancer cells].

Li J, Song LL, Zhong M.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):170-4. doi: 10.3760/cma.j.issn.0253-3766.2013.03.003. Chinese.

PMID:
23879995
19.

Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.

Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K.

Cancer. 2010 Jun 1;116(11):2621-34. doi: 10.1002/cncr.24987.

20.

Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.

Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, Tobiume M, Zennami K, Katsuda R, Honda N.

Oncol Rep. 2008 Jan;19(1):57-63.

PMID:
18097576

Supplemental Content

Support Center